SECOND AMENDED AND RESTATED LICENSE AGREEMENTLicense Agreement • May 24th, 2010 • Immunosyn Corp • Biological products, (no disgnostic substances) • California
This second amended and restated license agreement (the “Agreement”) is made on the 21st day of May, 2010 effective as of the 26th day of September, 2006, by and between Argyll Biotechnologies, LLC, a closely-held Delaware limited liability company having a principal office at 10815 Rancho Bernardo Road, Suite 101, San Diego, California 92127 (“Argyll Biotech”), and Immunosyn Corporation, a Delaware corporation having a principal office at 10815 Rancho Bernardo Road, Suite 101, San Diego, California 92127 (“Immunosyn”), either or both of which may be referred to as a Party or the Parties to this Agreement.
EMPLOYMENT AGREEMENTEmployment Agreement • October 23rd, 2007 • Immunosyn Corp • Biological products, (no disgnostic substances) • California
EMPLOYMENT AGREEMENT effective as of October 22, 2007 (the “Commencement Date”) by and between David Criner (“Executive”), and Immunosyn Corporation, a Delaware corporation (the “Company”) by or through its officers (this “Agreement”).
Lock-Up AgreementLock-Up Agreement • October 6th, 2006 • Immunosyn Corp
In order to induce Immunosyn Corporation, a Delaware corporation (the “Company”), to register my shares of the Company’s Common Stock, par value $0.0001 per share (“Common Stock”), the undersigned hereby agrees that for a period of twelve (12) months following the effective date of the prospectus (the “Prospectus”) filed by the Company with the Securities and Exchange Commission in connection with such offering, the undersigned will not, without the prior written consent of the Company, directly or indirectly:
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT OF STEPHEN FERRONEEmployment Agreement • May 18th, 2009 • Immunosyn Corp • Biological products, (no disgnostic substances)
SECOND AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made by and between IMMUNOSYN CORPORATION, a Delaware corporation (the “Company”), and STEPHEN FERRONE (the “Executive”).
Amended and Restated Lock-Up AgreementImmunosyn Corp • March 30th, 2007 • Biological products, (no disgnostic substances)
In order to induce Immunosyn Corporation, a Delaware corporation (the “Company”), to register my shares of the Company’s Common stock, par value $0.0001 per share (“Common Stock”), the undersigned hereby agrees that for a period of twelve (12) months following the effective date of the prospectus (the “Prospectus”) filed by the Company with the Securities and Exchange Commission in connection with such offering, the undersigned will not, without the prior written consent of the Company, directly or indirectly:
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT OF STEPHEN FERRONEEmployment Agreement • November 19th, 2007 • Immunosyn Corp • Biological products, (no disgnostic substances)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), effective as of November 15, 2007, is made by and between IMMUNOSYN CORPORATION, a Delaware corporation (the “Company”), and STEPHEN FERRONE (the “Executive”).
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT OF DAVID CRINEREmployment Agreement • November 19th, 2007 • Immunosyn Corp • Biological products, (no disgnostic substances)
FIRST AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”), effective as of November 15, 2007, is made by and between IMMUNOSYN CORPORATION, a Delaware corporation (the “Company”), and DAVID CRINER (the “Executive”).
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT OF STEPHEN FERRONEEmployment Agreement • April 16th, 2010 • Immunosyn Corp • Biological products, (no disgnostic substances)
THIRD AMENDMENT TO EMPLOYMENT AGREEMENT (the “Amendment”) is made by and between IMMUNOSYN CORPORATION, a Delaware corporation (the “Company”), and STEPHEN FERRONE (the “Executive”).
LICENSE AGREEMENTLicense Agreement • October 6th, 2006 • Immunosyn Corp • California
THIS LICENSE AGREEMENT (“Agreement”) is made effective as of the ___day of September, 2006, by and between Argyll Biotechnologies, LLC, a closely-held Delaware limited liability company having a principal office at 4225 Executive Square, Suite 260, La Jolla, California, 92037 (“Argyll Biotech”) and Immunosyn Corporation, a Delaware corporation having a principal office at 4225 Executive Square, Suite 260, La Jolla, California 92037 (“Immunosyn”).
